Jan 04, 2024 7:37am EST Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference
Dec 06, 2023 7:00am EST Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma
Nov 08, 2023 7:05am EST Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy
Oct 31, 2023 8:00am EDT Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
Oct 31, 2023 8:00am EDT Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control
Oct 25, 2023 8:06am EDT Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023
Oct 23, 2023 4:15am EDT Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO
Sep 11, 2023 8:00am EDT Dr. Karen Chagin Joins Adaptimmune as Senior Vice President of Early-Stage Development
